<DOC>
	<DOC>NCT00878709</DOC>
	<brief_summary>The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.</brief_summary>
	<brief_title>Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Stage II through IIIC HER2/erbB2 positive breast cancer with node positive disease. Been treated for early breast cancer with standard of care duration of trastuzumab. Could have been treated neoadjuvantly but have not reached pCR. Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry. History of heart disease. QTc interval &gt;0.45 seconds History of gastrointestinal disease with diarrhea as the major symptom.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HER-2/erbB-2 positive breast cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>neratinib</keyword>
	<keyword>HKI-272</keyword>
</DOC>